Skip to main content
logo
Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.500
-0.020 (-1.32%)
At close: Oct 29, 2026, 4:00 PM EDT
1.480
-0.020 (-1.33%)
After-hours: Oct 29, 2026, 4:57 PM EDT

Innate Pharma Cash Flow Statement

Millions EUR. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-47.46-49.18-49.47-7.57-58.1-52.81
Depreciation & Amortization
1.291.381.995.094.414.6
Loss (Gain) From Sale of Assets
0.20.020.02-0.52--0.37
Asset Writedown & Restructuring Costs
----41-
Loss (Gain) From Sale of Investments
-0.29-0.45-1.34-1.591.37-0.99
Stock-Based Compensation
2.082.573.944.264.252.62
Other Operating Activities
-0.783.53-1.21-0.130.43-1.62
Change in Accounts Receivable
8.231.6551.81---
Change in Accounts Payable
-0.77-0.97-1.01---
Change in Unearned Revenue
-3.06-0.62-7.04---
Change in Other Net Operating Assets
-1.69-10.32-4.11-32.09-12.5-9.89
Operating Cash Flow
-42.64-52.76-6.9-32.56-19.16-58.46
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0.17-0.14-0.39-0.35-0.54-0.93
Sale of Property, Plant & Equipment
---0.15-0.01
Sale (Purchase) of Intangibles
----2-0.59-0.4
Investment in Securities
2.017.049.5922.773-
Other Investing Activities
0.510.3900.06-00.41
Investing Cash Flow
2.357.299.220.631.88-0.92

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-----28.7
Long-Term Debt Repaid
--8.91-8.94-2.36-2.03-2.07
Net Debt Issued (Repaid)
-6.82-8.91-8.94-2.36-2.0326.63
Issuance of Common Stock
0.0514.982.930.40.20.5
Other Financing Activities
------0.31
Financing Cash Flow
-6.776.07-6.01-1.97-1.8326.82

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.181.09-0.510.27-0.43-0.48
Miscellaneous Cash Flow Adjustments
---00-0
Net Cash Flow
-47.24-38.3-4.21-13.62-19.53-33.04

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-42.81-52.9-7.29-32.91-19.69-59.39
Free Cash Flow Growth
------
Free Cash Flow Margin
-436.45%-587.40%-36.22%-53.39%-34.14%-240.40%
Free Cash Flow Per Share
-0.46-0.59-0.09-0.41-0.25-0.75
Levered Free Cash Flow
-28.96-34.0717.12-27.07-32.74-15.02
Unlevered Free Cash Flow
-28.72-33.817.47-26.67-32.56-14.82

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
-----0.31
Change in Working Capital
2.33-10.6339.16-32.09-12.5-9.89
SEC Filings: 10-K · 10-Q